Health and Healthcare

Why This Parkinson's Study Could Be Huge

courtesy of the U.S. Food and Drug Administration

Alterity Therapeutics Ltd. (NASDAQ: ATHE) says it has received an update from the U.S. Food and Drug Administration (FDA) regarding its Parkinson’s treatment. Shareholders were happy, as the stock more than doubled in Tuesday’s session.

The FDA gave guidance on the development pathway for ATH434 (previously PBT434), the company’s lead compound for the treatment of multiple system atrophy (MSA), a Parkinsonian disorder.

Alterity recently met with the FDA following the successful completion of its Phase 1 clinical trial last year and further data analysis. The pre-IND (Investigational New Drug) meeting was to obtain input on the clinical development plan for ATH434, including feedback on the Phase 2 study design.

Ultimately, the company reached an agreement with the FDA on the nonclinical investigations required to support the Phase 2 study. Additionally, the FDA agreed to key aspects of the Phase 2 study design, including the proposed patient population, safety monitoring plan and strategy for evaluating drug exposure during the study.

Currently there are no approved treatments for MSA. As a result, there is no regulatory precedent regarding accepted efficacy endpoints. So, the FDA and Alterity will work together to develop an endpoint that is best suited for the MSA patients to be studied.

Separate from Alterity’s U.S. strategy, the company also is pursuing a regulatory pathway in Europe and Australia.

Alterity stock traded up about 118% to $1.27 on Tuesday, in a 52-week range of $0.28 to $1.63.

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

 

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.